Open Access<p>Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer</p>
Author(s) -
Jiangping Yang,
Jiaqi Han,
Maolang Tian,
Kun Tian,
Wenjun Liao,
Yan Xi
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s284556
Subject(s) - fulvestrant , medicine , cost effectiveness , oncology , breast cancer , cancer , gynecology , estrogen receptor , risk analysis (engineering)
Ribociclib has provided significant improvements in progression-free survival (PFS) and overall survival (OS) of postmenopausal patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). However, given the high cost of ribociclib, its value must be evaluated based on cost-effectiveness. Thus, we aimed to explore the cost-effectiveness of ribociclib for postmenopausal patients with HR-positive and HER2-negative ABC.